Biomarkers for PD-1/PD-L1 Blockade Therapy in Non–Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

• Published in: Clinical lung cancer Vol. 17; no. 5; pp. 350 - 361
• Main Authors: Chae, Young Kwang, Pan, Alan, Davis, Andrew A., Raparia, Kirtee, Mohindra, Nisha A., Matsangou, Maria, Giles, Francis J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2016
• Subjects: Antineoplastic Agents - pharmacology; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; Biomarkers; Biomarkers, Tumor - immunology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Gene Expression Regulation, Neoplastic; Hematology, Oncology and Palliative Medicine; Humans; Immunotherapy; Immunotherapy - methods; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; NSCLC; Patient Selection; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Programmed cell death-1 protein ligand; Programmed cell death-1 protein receptor; Pulmonary/Respiratory; Tumor Microenvironment; Biomarkers; NSCLC; Programmed cell death-1 protein receptor; Programmed cell death-1 protein ligand; Immunotherapy

Immunotherapy has emerged as a promising treatment modality in cancer therapy. With improved understanding of how to tip the balance of immune homeostasis, novel therapeutics targeting immune checkpoints have been developed, with durable responses observed in multiple solid tumors, including melanom...